Comparison 60. NewBontA [Neuronox®] 20 units versus OnabotulinumtoxinA 20 units one treatment in glabellar lines.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
60.1 Participant assessment of success by analysing scores and scales	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
60.1.1 4 weeks	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
60.1.2 8 weeks	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
60.1.3 12 weeks	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
60.1.4 16 weeks	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
60.2 Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
60.3 Physician assessment of success by analysing scores and scales	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
60.3.1 4 weeks	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
60.3.2 8 weeks	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
60.3.3 12 weeks	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
60.3.4 16 weeks	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
60.4 Total adverse events	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected